Gainers

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares jumped 167.7% to close at $2.20 on Thursday after the company announced it has entered into an exclusive license agreement with GSK for Spero's late-stage antibiotic asset, tebipenem HBr. Spero Therapeutics will receive $66 million upfront, with potential for future milestone payments, and tiered royalties. Avenue Therapeutics, Inc. (NASDAQ:ATXI) gained 105.9% to close at $0.44 after the company received meeting minutes from the FDA regarding a meeting conducted on August 9, 2022, for IV Tramadol. The company also announced the effectiveness of its 1-for-15 reverse split on Sept. 23. Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 46.4% to close at...